Файл: "Клинические рекомендации "Артериальная гипертензия у взрослых".pdf

141. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens 2005; 23: 2113 - 2118.
142. Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008; 26: 1282 - 1289.
143. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs:
meta-analyses of randomized trials. J Hypertens 2016; 34: 1921 - 1932.
144. Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation 2011; 123: 1611 - 1621.
145. Fried LF, Emanuele N, Zhang JH, et al. NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892 - 1903.
146. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547 - 1559.
147. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - overview and meta-analyses. J
Hypertens 2015; 33: 195 - 211.
148. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008; 26: 819 -
824.
149. Brown MJ, Williams B, Morant SV, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol 2016; 4: 136 - 147.
150. Rimoldi SF et al. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis. The Journal of Clinical Hypertension 17.3 (2015): 193 - 199.
151. Wald DS et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. The American journal of medicine 122.3 (2009): 290 - 300.
152. Kang Seng et al. A systematic review and meta-analysis of the efficacy and safety of a fixed,
low-dose perindopril-indapamide combination as first-line treatment of hypertension. Clinical therapeutics
26.2 (2004): 257 - 270.
153. Webb AJS et al. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. The Lancet 375.9718 (2010): 906 - 915.
154. Чазова И.Е., Мычка В.Б. Новые возможности в лечении больных с метаболическим синдромом: результаты исследования ALMAZ, Системные гипертензии 2006; 2: 14 - 17.
155. Schlaich MP. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY study. International journal of
КонсультантПлюс_надежная_правовая_поддержка_www.consultant.ru_Страница_69_из_134Документ_предоставленКонсультантПлюс'>КонсультантПлюс
надежная правовая поддержка
www.consultant.ru
Страница 69 из 134
Документ предоставлен
КонсультантПлюс
Дата сохранения: 07.05.2021
"Клинические рекомендации "Артериальная гипертензия у взрослых"
(утв. Минздравом России)

hypertension 2013 (2013).
156. Rayner B. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? Current medical research and opinion 20.3 (2004): 359 - 367.
157. Bhatt DL, Kandzari DE, O'Neill WW, et al. For the Symplicity HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393 - 1401.
158. Mathiassen ON, Vase H, Bech JN, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens
2016; 34: 1639 - 1647.
159. DiBona GF. Physiology in perspective: the wisdom of the body. Neural control. of the kidney. Am
J Physiol Regul Integr Comp Physiol 2005; 289: R633 - R641.
160. Mahfoud F, Bohm M, Azizi M et al. Proceedings from the European Clinical Consensus
Conference for Renal Denervation: considerations on future clinical trial design. Eur Heart J 2015; 36: 2219 -
2227.
161. Narkiewicz K, Ratcliffe LE, Hart EC, et al. Unilateral carotid body resection in resistant hypertension: a safety and feasibility trial. JACC Basic Transl Sci 2016; 1: 313 - 324.
162. Bohm M, Mahfoud F, Ukena C et al. GSR Investigators. First report of the Global SYMPLICITY
Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension
2015; 65: 766 - 774.
163. Ng FL, Saxena M, Mahfoud F, et al. Device-based therapy for hypertension. Curr Hypertens Rep
2016; 18: 61.
164. Burchell AE, Lobo MD, Sulke N, et al. Arteriovenous anastomosis: is this the way to control hypertension? Hypertension 2014; 64: 6 - 12.
165. Kario K. et al. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs.
ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by
Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring - The
NOCTURNE Study-//Circulation Journal. - 2017. - Т. 81. - N. 7. - С. 948 - 957.
166. Tsai WC, Wu HY, Peng YS, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med 2017; 177: 792 - 799.
167. Jafar TH, Stark PC, Schmid CH, et al. AIPRD Study Group. Progression of chronic kidney disease:
the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244 - 252.
168. Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol 2014; 64: 588 -
597.
КонсультантПлюс
надежная правовая поддержка
www.consultant.ru
Страница 70 из 134
Документ предоставлен
КонсультантПлюс
Дата сохранения: 07.05.2021
"Клинические рекомендации "Артериальная гипертензия у взрослых"
(утв. Минздравом России)

169. Bakris GL, Sarafidis PA, Weir MR, et al. ACCOMPLISH Trial Investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events
(ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173
- 1181.
170. Xie X, Atkins E, Lv J et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016; 387: 435 - 443.
171. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
172. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart
Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129 - 2200.
173. Emdin CA et al. Meta-analysis of large-scale randomized trials to determine the effectiveness of inhibition of the renin-angiotensin aldosterone system in heart failure. The American journal of cardiology
116.1 (2015): 155 - 161.
174. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis,
and treatment//Eur heart J 2010; 32(6): 670 - 679.
175. Nanayakkara S, Kaye DM. Management of heart failure with preserved ejection fraction: a review.
Clinical therapeutics 37.10 (2015): 2186 - 2198.
176. Shah SJ et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 2016; 134(1): 73 - 90.
177. Shah RV, Akshay SD, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. Journal of cardiac failure 16.3 (2010): 260 - 267.
178. Soliman EZ et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation 2017: 136(5):
440 - 450.
179. Klingbeil AU et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. The American journal of medicine 115.1 (2003): 41 - 46.
180.
B, Kjell P, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. 1992. P. 95 - 110.
181. Lip GYH, Coca A, Kahan T et al. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on. Hypertension, endorsed by the
Heart Rhythm Society (HRS), Asia-Pacific Heart. Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion. Cardiaca y Electrofisiologia (SOLEACE). Europace 2017; 19: 891 - 911.
КонсультантПлюс_надежная_правовая_поддержка_www.consultant.ru_Страница_72_из_134Документ_предоставленКонсультантПлюс'>КонсультантПлюс
надежная правовая поддержка
www.consultant.ru
Страница 71 из 134
Документ предоставлен
КонсультантПлюс
Дата сохранения: 07.05.2021
"Клинические рекомендации "Артериальная гипертензия у взрослых"
(утв. Минздравом России)

182. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur Heart J. 2016 Oct 7; 37(38): 2893 - 2962.
183. Hart RG et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Annals of internal medicine 131 (1999): 492 - 501; 536, 556.
184. Фибрилляция и трепетание предсердий у взрослых. Клинические рекомендации.
Всероссийское научное общество специалистов поклинической электрофизиологии, аритмологии и электростимуляции. Общество специалистов по неотложной кардиологии. 2016.
185. Arima H, Chalmers J, Woodward M, et al. PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006;
24: 1201 - 1208.
186. Rodriguez-Luna D, Pineiro S, Rubiera M, et al. Impact of blood pressure changes and courseon hematoma growth in acute intracerebral hemorrhage. Eur J Neurol. 2013; 20: 1277 - 1283.
187. Sakamoto Y, Koga M, Yamagami H et al. Systolic blood pressure afterintravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factorassessment and improvement intracerebral hemorrhage study. Stroke. 2013; 44: 1846 - 1851.
188. Anderson CS, Heeley E, Huang Y, et al. INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013; 368: 2355 - 2365.
189. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 2016; 375: 1033 - 1043.
190. Tsivgoulis G, Katsanos AH, Butcher KS et al. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. Neurology 2014; 83: 1523 - 1529.
191. T. Steiner et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. International Journal of Stroke, Vol. 9, October 2014, p. 840 - 855.
192. Hemphill et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. A
Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.
Stroke. 2015; 46: 2032 - 2060. doi: 10.1161/STR.0000000000000069].
193. Powers WJ et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic
Stroke. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke
Association. Stroke 2018; 49 (3): e46 - e138.
194. Lee M, Ovbiagele B, Hong KS, et al. Effectof blood pressure lowering in early ischemic stroke:
meta-analysis. Stroke. 2015; 46: 1883 - 1889.
195. Zhao R, Liu FD, Wang S et al. Blood pressure reduction in the acute phase of an ischemic stroke does not improve short- or long-term dependency or mortality: a meta-analysis of current literature. Medicine
(Baltimore). 2015; 94: e896.
196. Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy,
and outcome inischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe
КонсультантПлюс
надежная правовая поддержка
www.consultant.ru
Страница 72 из 134
Документ предоставлен
КонсультантПлюс
Дата сохранения: 07.05.2021
"Клинические рекомендации "Артериальная гипертензия у взрослых"
(утв. Минздравом России)

Implementation of Thrombolysis in Stroke-International StrokeThrombolysis Register (SITS-ISTR). Stroke
2009; 40: 2442 - 2449.
197. Wu W, Huo X, Zhao X, et al. Relationship between blood pressure and outcomes in acute ischemic stroke patients administered lytic medication in the TIMS-China Study. PLoS One 2016; 11: e0144260.
198. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. The Lancet 358. 9287
(2001): 1033 - 1041.
199. White CL, Szychowski JM, Pergola PE et al. Secondary Prevention of Small Subcortical Strokes
Study Investigators. Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary
Prevention of Small Subcortical Strokes study experience. J Am Geriatr Soc 2015; 63: 722 - 729.
200. SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control.
New England Journal of Medicine 2015; 373(22): 2103 - 2116.
201. Wang Ji-Guang et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 37.7 (2006): 1933 - 1940.
202. Lane D.A., Lip G.Y.H. Treatment of hypertension in peripheral arterial disease//Cochrane database of systematic reviews. - 2013. - N. 12.
203. Vidal-Petiot E. et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. The
Lancet 2016; 388(10056): 2142 - 2152.
204. Zanchetti A, Hennig M, Hollweck R et al. Baseline values but not treatment-induced changes incarotid intima-media thickness predict incident cardiovascular events in treatedhypertensive patients:
findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation 2009; 120: 1084 - 1090.
205. Zanchetti A, Crepaldi G, Bond MG, et al. PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS - a randomized double-blind trial. Stroke 2004; 35: 2807 - 2812.
206. Myou S, Fujimura M, Kamio Y, et al. Effect of losartan, a type 1 angiotensin II receptor antagonist,
on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. Am J Respir Crit Care
Med 2000; 162: 40 - 4.
207. Chiu KY, Li JG, Lin Y. Calcium channel blockers for lung function improvement in asthma: A
systematic review and meta-analysis. Ann Allergy Asthma Immunol 2017; 119(6): 518 - 523. e3.
208. Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensinconverting enzyme inhibitors: a systematic review and meta-analysis. Am J
Cardiovasc Drugs 2012; 12: 263 - 77.
209. Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009; 10: 45.
КонсультантПлюс
надежная правовая поддержка
www.consultant.ru
Страница 73 из 134
Документ предоставлен
КонсультантПлюс
Дата сохранения: 07.05.2021
"Клинические рекомендации "Артериальная гипертензия у взрослых"
(утв. Минздравом России)

210. Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond) 2012; 123(8): 487 - 498.
211. Tanaka H, Teramoto S, Oashi K, et al. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation.
2001; 104(3): 281 - 285.
212. Сукмарова З.Н., Литвин А.Ю., Чазова И.Е., Рогоза А.Н. Эффективность комплексной медикаментозной и CPAP-терапии у пациентов с артериальной гипертонией 2 - 3-й степени и тяжелой степенью синдрома обструктивного апноэ во время сна. ФГУ РКНПК Минздравсоцразвития РФ,
Москва. Системные гипертензии, 2011: 8(1), 40.
213. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery:
cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment andmanagement of the European Society of Cardiology (ESC) and the European Society of
Anaesthesiology (ESA). Eur Heart J 2014; 35: 2383 - 2431.
214. Futier E, Lefrant JY, Guinot PG et al. Effect of individualized vs standardblood pressure management strategies on postoperative organ dysfunctionamong high-risk patients undergoing major surgery:
a randomized clinical trial. JAMA 2017; 318: 1346 - 1357.
215. London MJ, Hur K, Schwartz GG, Henderson WG. Association of perioperative beta-blockade with mortality and cardiovascular morbidity following major non-cardiac surgery. JAMA 2013; 309: 1704 - 1713.
216. Andersson C, Merie C, Jorgensen M, et al. Association of beta-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwidecohort study. JAMA Intern Med 2014; 174: 336 - 344.
217. Blessberger H, Kammler J, Domanovits H, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev. 2018; 3: CD004476.
218. Lederballe Pedersen O, Mikkelsen E, Lanng Nielsen J, Christensen NJ. Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin. Eur J Clin Pharmacol. 1979 Apr 17; 15(3): 215 - 7.
219. Gupta P, Patel P, Strauch B et al. Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence. Hypertension 2017; 70: 1042 - 1048.
220. Noubiap JJ, Nansseu JR, Nyaga UF et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients Heart 2019; 105: 98 - 105.
221. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistanthypertension: results from a randomized trial. Hypertension 2009; 54: 475 - 481.
222. Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2017; 39: 257 - 263.
223. Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patientswith resistant hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ 2016; 25: 1021 - 1030.

224. Huang Y, Huang W, Mai W, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens 2017; 35: 677 - 688.
225. Briasoulis A, Androulakis E, Palla M, et al. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens 2016; 34: 593 - 599.
226. Grassi G, Seravalle G, Trevano FQ, et al. Neurogenic abnormalities in masked hypertension.
Hypertension 2007; 50: 537 - 542.
227. Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med 2018; 378: 1509 - 1520.
228. Cuspidi C, Rescaldani M, Tadic M, et al. White-coat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a meta-analysis. J Hypertens 2015; 33: 24 - 32.
229. Mancia G, Bombelli M, Facchetti R, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens 2009; 27: 1672 - 1678.
230. Tientcheu D, Ayers C, Das SR, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am
Coll Cardiol 2015; 66: 2159 - 2169.
231. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 2009; 54: 226 - 232.
232. Thakkar H.V., Pope A., & Anpalahan, M. Masked Hypertension: A Systematic Review. Heart,
Lung and Circulation. 2019.
233. Ogedegbe G, Agyemang C, Ravenell JE. Masked hypertension: evidence of the need to treat. Curr
Hypertens Rep 2010; 12: 349 - 355.
234. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta-analysis. American journal of hypertension 24.1 (2011): 52 - 58.
235. Agarwal R et al. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension 57.1 (2011): 29 - 38.
236. Rolnik DL, Wright D, Poon LC et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377: 613 - 622.
237. Easterling T. et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial//The Lancet. -
2019. - Т. 394. - N. 10203. - С. 1011 - 1021.
238. Ogihara T, Saruta T, Rakugi H, et al. COLM Investigators. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. Hypertens Res 2015; 38: 89 - 96.
239. Thomopoulos C, Parati G., Zanchetti A. Effects of blood pressure-lowering treatment on
КонсультантПлюс
надежная правовая поддержка
www.consultant.ru
Страница 75 из 134
Документ предоставлен
КонсультантПлюс
Дата сохранения: 07.05.2021
"Клинические рекомендации "Артериальная гипертензия у взрослых"
(утв. Минздравом России)